Professor Reinhold Kreutz - Declining Renal Function and Non-Valvular Atrial Fibrillation – An Important Consideration?
For full prescribing information, refer to the package insert approved by the Medicines Authority (SAHPRA).
XARELTO® 10 (Rivaroxaban 10 mg): South Africa: S4 Reg. No.: 42/8.2/1046; Namibia: NS2 10/8.2/0463; Botswana: S2 BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5362; Mauritius: R12697/02/14.
XARELTO® 15 (Rivaroxaban 15 mg): South Africa: S4 Reg. No.: 46/8.2/0111; Namibia: NS2 12/8.2/0006; Botswana: S2 BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5363; Mauritius: R11772/02/14.
XARELTO® 20 (Rivaroxaban 20 mg): South Africa: S4 Reg. No.: 46/8.2/0112; Namibia: NS2 12/8.2/0007; Botswana: S2 BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364; Mauritius: R12698/02/14.
Applicant/HCR: Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609.
PP-XAR-ZA-0044-1